Current concepts and new developments in the treatment of psoriatic arthritis

Rheumatology

Volumn 42, Issue 10, 2003, Pages 1138-1148

  Pipitone, N ^a   Kingsley, G H ^b   Manzo, A ^c   Scott, D L ^a   Pitzalis, Costantino ^d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Disease modifying agents; Drug therapy; Glucocorticoids; Non steroidal anti inflammatory drugs; Psoriatic arthritis; TNF blockers

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AURANOFIN; AZATHIOPRINE; BROMOCRIPTINE; CALCITRIOL; CELECOXIB; CHLOROQUINE; COLCHICINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DICLOFENAC; ETRETIN; GLUCOCORTICOID; GOLD SALT; KETOCONAZOLE; LEFLUNOMIDE; METHOTREXATE; MISOPROSTOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NABUMETONE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SALAZOSULFAPYRIDINE; SOMATOSTATIN; SULFANILAMIDE DERIVATIVE; THIOMALATE SODIUM; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; ARTHRITIS; BONE MARROW APLASIA; CLINICAL TRIAL; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; EXPERIENCE; GASTROINTESTINAL TOXICITY; GLUCOSE INTOLERANCE; HEMATEMESIS; HUMAN; INFECTION; JOINT DESTRUCTION; LIVER TOXICITY; MEDICAL LITERATURE; MEDLINE; MONARTHRITIS; NEPHROTOXICITY; OSTEOPOROSIS; PELVIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; SPONDYLITIS; SYNOVITIS; TREATMENT INDICATION; TREATMENT OUTCOME; VERTIGO;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0141962680     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg363     Document Type: Review

References (99)

1. Blumberg BS, Bunim JJ, Calkins E, Pirani CL, Zvaifler NJ. ARA nomenclature and classification of arthritis and rheumatism (tentative). Arthritis Rheum 1964;7:93-7.
2. Wright V. A unifying concept for the spondyloarthropathies. Clin Orthop Related Res 1979;143:8-14.
3. McGonagle D, Khan MA, Marzo-Ortega H, O'Connor P, Gibbon W, Emery P. Enthesitis in spondyloarthropathy. Curr Opin Rheumatol 1999;11:244-50.
4. McGonagle D, Gibbon W, O'Connor P, Green M, Pease C, Emery P. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 1998;41:694-700.
5. Marsal S, Armadans-Gil L, Martinez M, Gallardo D, Ribera A, Lience E. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology 1999;38:332-7.
6. Salvarani C, Cantini F, Olivieri I et al. Isolated peripheral enthesitis and/or dactylitis: a subset of psoriatic arthritis. J Rheumatol 1997;24:1106-10.
7. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
8. Salvarani C, Olivieri I, Cantini F, Macchioni L, Boiardi L. Psoriatic arthritis. Curr Opin Rheumatol 1998;10: 299-305.
9. Gladman DD. Psoriatic arthritis: recent advances in pathogenesis and treatment. Rheum Dis Clin North Am 1992;18:247-56.
10. Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs 2000;9:1511-22.
11. Cuellar ML, Citera G, Espinoza LR. Treatment of psoriatic arthritis. Bailliere's Clin Rheumatol 1994;8: 483-98.
12. Griffiths CE. Therapy for psoriatic arthritis: sometimes a conflict for psoriasis. Br J Rheumatol 1997;36:409-10.
13. Sarzi-Puttini P, Santandrea S, Boccassini L, Panni B, Caruso I. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001;19:S17-S20.
14. Scott DL, Palmer RH. Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. Aliment Pharmacol Ther 2000;14:443-52.
15. Bennett A, Tavares IA. COX-2 inhibitors compared and contrasted. Expert Opin Pharmacother 2001;2:1859-76.
16. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Br Med J 2002;325:619
17. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002;25:537-44.
18. Espinoza LR, Cuellar ML. Psoriatic arthritis: management. In: Klippel JH, Dieppe PA (eds). Rheumatology. London: Mosby, 1998:1-6.
19. Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 1968;80:771-93.
20. Wright V. Psoriatic arthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB (eds). Textbook of rheumatology. Philadelphia: Saunders, 1989:1021-31.
21. Fiocco U, Cozzi L, Rigon C et al. Arthroscopic synovectomy in rheumatoid and psoriatic knee joint synovitis: long-term outcome. Br J Rheumatol 1996;35:463-70.
22. Stucki G, Bozzone P, Treuer E, Wassmer P, Felder M. Efficacy and safety of radiation synovectomy with yttrium-90: a retrospective long-term analysis of 164 applications in 82 patients. Br J Rheumatol 1993;32: 383-6.
23. Bulbul R, Williams WV, Schumacher HR Jr. Psoriatic arthritis. Diverse and sometimes highly destructive. Postgrad Med 1995;97:97-6, 108.
24. Fournie B, Crognier L, Arnaud C et al. Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients. Rev Rhum Engl Ed 1999;66: 446-56.
25. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-6.
26. Smith DL, Wernick R. Exacerbation of psoriasis by chrysotherapy. Arch Dermatol 1991;127:268-70.
27. Jones G, Crotty M, Brooks P. Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group. Br J Rheumatol 1997;36:95-9.
28. Taccari E, Spadaro A, Riccieri V. Correlations between peripheral and axial radiological changes in patients with psoriatic polyarthritis. Rev Rhum Engl Ed 1996;63: 17-23.
29. Scarpa R. Psoriatic arthritis. Is something changing? Adv Exp Med Biol 1999;455:207-14.
30. Blackmore MG, Gladman DD, Husted J, Long JA, Farewell VT. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995;22:886-93.
31. Ostergaard M, Stoltenberg M, Henriksen O, Lorenzen I. Quantitative assessment of synovial inflammation by dynamic gadolinium-enhanced magnetic resonance imaging. A study of the effect of intra-articular methylprednisolone on the rate of early synovial enhancement. Br J Rheumatol 1996;35:50-9.
32. Palmer WE, Rosenthal DI, Schoenberg OI et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995;196: 647-55.
33. Cuellar ML, Espinoza LR. Management of spondyloarthropathies. Curr Opin Rheumatol 1996;8:288-95.
34. Gladman DD, Farewell VT. The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. Arthritis Rheum 1995;38:845-50.
35. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995;22:675-9.
36. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10.
37. Huizinga TW, Keijsers V, Yanni G et al. Are differences in interleukin 10 production associated with joint damage? Rheumatology 2000;39:1180-8.
38. Salvarani C, Olivieri I, Cantini F, Macchioni L, Boiardi L. Psoriatic arthritis. Curr Opin Rheumatol 1998;10: 299-305.
39. Lacaille D, Stein HB, Raboud J, Klinkhoff AV. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? J Rheumatol 2000;27:1922-7.
40. Clark CM, Kirby B, Morris AD et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999;141:279-82.
41. Black RL, O'Brien WM, Van Scott EJ, Auerbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis. Double-blind study on 21 patients. J Am Med Assoc 1964;189:743-7.
42. Willkens RF, Williams HJ, Ward JR et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
43. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995;22:241-5.
44. Bressolle F, Bologna C, Kinowski JM, Sany J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis 1998;57:110-3.
45. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. London: British Medical Association, 2002.
46. Maurer TA, Zackheim HS, Tuffanelli L, Berger TG. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 1994;31:372-5.
47. Clegg DO, Reda DJ, Mejias E et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
48. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-9.
49. Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA. Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol 1993;32:923-5.
50. Combe B, Goupille P, Kuntz JL, Tebib J, Liote F, Bregeon C. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol 1996;35:664-8.
51. Gupta AK, Grober JS, Hamilton TA, Ellis CN, Siegel MT, Voorhees JJ, McCune WJ. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995;22:894 8.
52. Dougados M, van der Linden S, Leirisalo-Repo M et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
53. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998;25:1957-61.
54. Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1990;29:46-9.
55. Pitzalis C, Pipitone N. Psoriatic arthritis. J R Soc Med 2000;93:412-5.
56. Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995;32:78-88.
57. Raffayova H, Rovensky J, Malis F. Treatment with cyclosporin in patients with psoriatic arthritis: results of clinical assessment. Int J Clin Pharmacol Res 2000;20: 1-11.
58. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995;13:589-93.
59. Salvarani C, Macchioni P, Olivieri I et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28:2274-82.
60. Macchioni P, Boiardi L, Cremonesi T et al. The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A. Rheumatol Int 1998;18: 27-33.
61. Korstanje MJ, Bilo HJ, Stoof TJ. Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy. Br J Dermatol 1992;127: 501-4.
62. Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992;19:1724-6.
63. Bruckle W, Dexel T, Grasedyck K, Schattenkirchner M. Treatment of psoriatic arthritis with auranofin and gold sodium thiomalate. Clin Rheumatol 1994;13:209-16.
64. Palit J, Hill J, Capell HA et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990;29:280-3.
65. Carette S, Calin A, McCafferty JP, Wallin BA. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arthritis Rheum 1989;32:158-65.
66. Mader R, Gladman DD, Long J, Gough J, Farewell VT. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med 1995; 18:139-43.
67. Helliwell PS, Wright V. Psoriatic arthritis: clinical features. In: Klippel JH, Dieppe P (eds). Rheumatology. London: Mosby, 1998:1-8.
68. Manguso F, Oriente A, Peluso R, Oriente P. Leflunomide in psoriatic polyarthritis: an Italian pilot study. Arthritis Rheum 2001;44(9S):S92.
69. Liang GC, Barr WG. Long term follow-up of the use of leflunomide in recalcitrant psoriatic arthritis and psoriasis. Arthritis Rheum 2001;44(9S):S121.
70. Grundmann-Kollmann M, Mooser G, Schraeder P et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 2000;42:835-7.
71. Tong DW, Walder BK. Widespread plaque psoriasis responsive to mycophenolate mofetil. Australas J Dermatol 1999;40:135-7.
72. Seideman P, Fjellner B, Johannesson A. Psoriatic arthritis treated with oral colchicine. J Rheumatol 1987; 14:777-9.
73. McKendry RJ, Kraag G, Seigel S, al Awadhi A. Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis. Ann Rheum Dis 1993;52:826-8.
74. Kagan A, Husza'r M, Frumkin A, Rapoport J. Reversal of nephrotic syndrome due to AA amyloidosis in psoriatic patients on long-term colchicine treatment. Case report and review of the literature. Nephron 1999;82:348-53.
75. Hopkins R, Bird HA, Jones H, Hill J, Surrall KE, Astbury C, Miller A, Wright V. A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Ann Rheum Dis 1985;44:189-193.
76. Levy J, Barnett EV, MacDonald NS, Klinenberg JR, Pearson CM. The effect of azathioprine on gammaglobulin synthesis in man. J Clin Invest 1972;51:2233-8.
77. Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study. Arthritis Rheum 1990;33:1723-7.
78. Eulry F, Bauduceau B, Mayaudon H, Lechevalier D, Ducorps M, Magnin J. Therapeutic efficacy of bromocriptine in psoriatic arthritis (two case-reports). Rev Rhum Engl Ed 1995;62:607-8.
79. Buskila D, Sukenik S, Holcberg G, Horowitz J. Improvement of psoriatic arthritis in a patient treated with bromocriptine for hyperprolactinemia. J Rheumatol 1991;18:611-2.
80. Eulry F, Mayaudon H, Bauduceau B et al. [Blood prolactin under the effect of protirelin in spondylarthropathies. Treatment trial of 4 cases of reactive arthritis and 2 cases of psoriatic arthritis with bromocriptine]. Ann Med Interne (Paris) 1996;147:15-9.
81. Eibschutz B, Baird SM, Weisman MH et al. Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report. Arthritis Rheum 1995;38:1604-9.
82. Matucci-Cerinic M, Pignone A, Lotti T, Partsch G, Livi R, Cagnoni M. Gold salts and somatostatin: a new combined analgesic treatment for psoriatic arthritis. Drugs Exp Clin Res 1992;18:53-61.
83. Klippel JH, Dieppe PA (eds). Rheumatology. Philadelphia: Mosby, 1994.
84. Fierlbeck G, Rassner G. Treatment of psoriasis and psoriatic arthritis with interferon gamma. J Invest Dermatol 1990;95:138S-141S.
85. Snellman E, Lauharanta J, Reunanen A et al. Effect of heliotherapy on skin and joint symptoms in psoriasis: a 6-month follow-up study. Br J Dermatol 1993;128:172-7.
86. Vahlquist C, Larsson M, Ernerudh J, Berlin G, Skogh T, Vahlquist A. Treatment of psoriatic arthritis with extracorporeal photochemotherapy and conventional psoralen-ultraviolet A irradiation. Arthritis Rheum 1996;39:1519-23.
87. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-51.
88. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25: 1544-52.
89. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44:2112-7.
90. Braun J, Sieper J. Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies? Ann Rheum Dis 2000;59:404 7.
91. Van den BF, Kruithof E, Baeten D, de Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
92. Antoni C, Dechant C, Lorenz H, Olgivie A, Kalden-Nemeth D, Kalden JR. Successful treatment of severe psoriatic arthritis with infliximab. [Abstract]. Arthritis Rheum 1999;42:S371.
93. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385-90.
94. Cunnane G, Madigan A, Murphy E, Fitzgerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology 2001;40:62-9.
95. Utset TO, Auger JA, Peace D et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. Arthritis Rheum 2001;44(9S):S92.
96. Kraan MC, van Kuijk AW, Dinant HJ et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002;46:2776-84.
97. Levy J, Paulus HE, Barnett EV, Sokoloff M, Bangert R, Pearson CM. A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum 1972;15:116-7.
98. Price R, Gibson T. D-penicillamine and psoriatic arthropathy. Br J Rheumatol 1986;25:228.
99. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.